{
  "id": 1784,
  "text": "0 3 0 \\mathrm { ) }$ ).No other scales derived from the EORTC QLQ-C30 or EORTC QLQX24 questionnaires had significant differences between the study groups.Monk et al.1665,1666 reported on a head-to-head RCT comparing an oral multitargeted antivascular agent (pazopanib) with an oral dual anti-EGFR and anti-HER2/neu tyrosine kinase inhibitor (lapatinib) among women with advanced and recurrent cervical ancer.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: 0 3 0 \\mathrm { ) }$ ).No other scales derived from the EORTC QLQ-C30 or EORTC QLQX24 questionnaires had significant differences between the study groups.Monk et al.1665,1666 reported on a head-to-head RCT comparing an oral multitargeted antivascular agent (pazopanib) with an oral dual anti-EGFR and anti-HER2/neu tyrosine kinase inhibitor (lapatinib) among women with advanced and recurrent cervica\n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "研究中比较了两种口服抗癌药物用于治疗晚期和复发性宫颈癌：一种是多靶点的抗血管生成剂帕唑帕尼（pazopanib），另一种是具有双重抗EGFR和抗HER2/neu活性的酪氨酸激酶抑制剂拉帕替尼（lapatinib）。这些药物在试验中被用于研究其疗效和安全性。",
  "query": "研究中比较了哪些抗癌药物以治疗晚期和复发性宫颈癌？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 研究中比较了哪些抗癌药物以治疗晚期和复发性宫颈癌？\n\n<reference text>: 0 3 0 \\mathrm { ) }$ ).No other scales derived from the EORTC QLQ-C30 or EORTC QLQX24 questionnaires had significant differences between the study groups.Monk et al.1665,1666 reported on a head-to-head RCT comparing an oral multitargeted antivascular agent (pazopanib) with an oral dual anti-EGFR and anti-HER2/neu tyrosine kinase inhibitor (lapatinib) among women with advanced and recurrent cervical ancer.\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "研究中比较了两种口服抗癌药物用于治疗晚期和复发性宫颈癌：一种是多靶点的抗血管生成剂帕唑帕尼（pazopanib），另一种是具有双重抗EGFR和抗HER2/neu活性的酪氨酸激酶抑制剂拉帕替尼（lapatinib）。这些药物在试验中被用于研究其疗效和安全性。"
}